Introducing Ivan Kairatov, a distinguished authority in biopharmaceutical innovation and technological advancements. With extensive experience in research and development, Ivan provides a unique perspective on the acquisition of Althea by PCI Pharma. This interview delves into how such strategic
Digital technology has become an indispensable element of modern healthcare systems, driving efficiency and enhancing patient outcomes. Ireland is currently witnessing a significant shift in its children's healthcare sector, spearheaded by a five-year agreement between Children’s Health Ireland
Could a simple blood test radically change how liver cancer is detected, especially for those at high risk? This question resonates strongly with recent developments in cancer diagnostics, notably with the FDA's recognition of EvoLiver™, a groundbreaking innovation by Mursla Bio. This designation
ICU Medical, a prominent medical device company based in California, is currently navigating significant regulatory challenges related to their infusion pumps. These challenges have emerged following an FDA warning, which highlighted the company's failure to adhere to essential regulatory
The field of acute coronary syndrome (ACS) care has witnessed significant advancements, driven by an evolving understanding of patient management practices and continuous clinical research efforts. These innovations encompass various aspects of treatment, from rethinking established protocols like
The Worcestershire Acute Hospitals NHS Trust recently faced significant hurdles in capturing real-time observations of sepsis patients through its electronic patient record (EPR) system. Sepsis, a potentially deadly medical emergency, necessitates swift treatment to prevent organ failure and death.
Chinese contract research organization GemPharmatech has expanded its presence in the United States with a new facility in San Diego, announced on April 17. The facility is designed for laboratories and housing genetically engineered mouse models, aimed at enhancing their capabilities in offering
Roche's Columvi, a bispecific antibody known as glofitamab, has been approved by the European Commission (EC) for use in combination with gemcitabine and oxaliplatin (GemOx) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not candidates for autologous stem
Colossal Biosciences, a leading biotechnology and genetic engineering company, has announced a groundbreaking achievement: the resurrection of the dire wolf, which went extinct about 12,500 years ago. Founded in 2025, the company is also working on bringing back the woolly mammoth and has already
INCOG, a contract development and manufacturing organization (CDMO), recently made a substantial investment to expand its capabilities in the sterile injectables sector. In February 2024, the company committed $75 million to install an Optima syringe and cartridge filling line, projected to be GMP
